Semaglutide 10mg

Peptide Science research editorial team.

Semaglutide 10mg Overview

Semaglutide 10mg from Peptide Science is supplied as a lyophilised vial at 10 mg for in-vitro and preclinical adipose / metabolic research. Semaglutide is a GLP-1 receptor agonist characterised in preclinical work for receptor-binding affinity and downstream incretin- or amylin-pathway signalling in pancreatic and adipose-tissue cell culture.

Receptor Profile and Class Background

Semaglutide is a 31-amino-acid synthetic analogue of human glucagon-like peptide-1 (GLP-1), characterised in preclinical research for high binding affinity at the GLP-1 receptor with extended half-life relative to native GLP-1. The molecule includes a C18 fatty-acid side chain at residue 26 that enables albumin binding, which is the structural feature underlying the extended in-vitro stability profile cited in preclinical literature. Browse the broader metabolic peptide research range for adjacent compounds.

Specifications

For lower-strength formats suited to shorter cell-culture series, see Semaglutide 3mg and Semaglutide 6mg.

Reconstitution and Handling

The lyophilised vial reconstitutes with bacteriostatic water at the working concentration set by the principal investigator. Material is sensitive to repeated freeze-thaw cycles; aliquoting reconstituted stock for single-use frozen storage is the standard preclinical handling practice cited in incretin-research literature.

Quality and Shipping

Each batch passes HPLC at greater than 99 percent purity, with mass-spectrometry identity confirmation against the theoretical mass. A Certificate of Analysis accompanies every order. Material is filled in a US laboratory under ISO 9001:2015-aligned quality systems and dispatched in temperature-monitored insulated packaging via overnight or two-day courier.

For laboratory research and development use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease, including obesity or type 2 diabetes. Has not been evaluated by the U.S. Food and Drug Administration. Branded therapeutic GLP-1, GIP, and dual-agonist medicines (Ozempic, Wegovy, Mounjaro, Zepbound) are prescription-only medicines in the United States and are not the same as research-grade compounds supplied for in-vitro work. Purchasers acknowledge they are qualified researchers age 21 or older and accept responsibility for compliance with all applicable federal, state, and local laws.